Pfizer's hardball offer for Icagen shares succeeds after two extensions
This article was originally published in Scrip
Executive Summary
Pfizer has said that its initial cash tender offer for the shares of pain drug developer Icagen has succeeded. The offer had required that a majority of Icagen shareholders agree to its deal of $6 per share. Shareholders who have yet to sell out have until 12 September to claim their $6 per share.